pharmaceutical companies

Federal regulators are pressing the Supreme Court to stop big pharmaceutical corporations from paying generic drug competitors to delay releasing their cheaper versions of brand-name drugs. They argue these deals deny American consumers, usually for years, steep price declines that can top 90 percent. (Photo Illustration by Tim Boyle/Getty Images)

Federal Regulators Look To Stop Billion Dollar Deals Between Drug Companies, Generic Brands

Federal regulators are pressing the Supreme Court to stop big pharmaceutical corporations from paying generic drug competitors to delay releasing their cheaper versions of brand-name drugs. They argue these deals deny American consumers, usually for years, steep price declines that can top 90 percent.

03/25/2013

Follow

Get every new post delivered to your Inbox.

Join 1,656 other followers